

PUBLICATIONS
PEER REVIEWED

CHRISTIAN MARTH

MEDIZINISCHE UNIVERSITÄT INNSBRUCK

456. Zhang J, Kelkar SS, Prabhu VS, Qiao Y, Grall V, Miles N, Marth C
Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe
BMJ Open 2024;14:e079447. doi: 10.1136/bmjopen-2023-079447
455. Ledermann J.A., Matias-Guiu X., Amant F., Concin N., Davidson B., Fotopoulou C., González-Martin A., Gourley C., Leary A., Lorusso D., Banerjee S., Chiva L., Cibula D., Colombo N., Croce S., Eriksson A.G., Falandry C., Fischerova D., Harter P., Joly F., Lazaro C., Lok C., Mahner S., Marmé F., Marth C., McCluggage W.G., McNeish I.A., Morice P., Nicum S., Oaknin A., Pérez-Fidalgo J.A., Pignata S., Ramirez P.T., Ray-Coquard I., Romero I., Scambia G., Sehouli J., Shapira-Frommer R., Sundar S., Tan D.S.P., Taskiran C., van Driel W.J., Vergote I., Planchamp F., Sessa C., Fagotti A.
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of Oncology 2024, doi.org/10.1016/j.annonc.2023.11.015.
454. Hasson SP, Ray-Coquard I, Marth C, Harter P
Surgery and HIPEC in relapse for all patients with ovarian cancer?
ESMO Open 2023, podcast
453. Heitz F, Marth C, Henry S, A Reuss, Cibula D, Gaba Garcia L, Colombo N, Schmalfeld B, de Gregorio N, Wimberger P, Hasenburg A, Sehouli J, Gropp-Meier M, Schouten PC, Hahnen E, Hauke J, Polleis S, Harter P
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial
Int J Gynecol Cancer 2023;33:1966–1969. doi:10.1136/ijgc-2023-004944
452. Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martin A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon T-W, Dubot C, Denschlag D, You B, Pujade-Lauraine E & Harter P for the PAOLA-1/ENGOT-ov25 investigators
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology (2023), <https://doi.org/10.1016/j.annonc.2023.05.005>

451. Harter P, Bogner G, Chiva L, Cibula D, Concin N, Fotopoulou C, Gonzales-Martin A, Guyon F, Heinzlmann-Schwarz V, Kridelka F, Mahner S, Marmé F, Marth C, Morice P, Novák Z, Papadia A, Ray-Coquard I, Redecha M, Redondo A, Schwameis R, Sehouli J, Undurrage M, Van Gorp T, Vergote I
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bull Cancer (2023), doi.org/10.1016/j.bulcan.2023.02.011
450. Wieser V, Tsubulak I, Reimer DU, Zeimet AG, Fiegl H, Hackl H, Marth C
An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer
Gynecologic Oncology 2023, Volume 170, 290-299; doi: 10.1016/j.ygyno.2023.01.034
449. Roser E, Harter P, Zocholl D, Denschlag D, Chekerov R, Wimberger P, Kurzeder C, Hasenburg A, Muallem Mz, Mustea A, Emons G, Zeimet Ag, Beck F, Arndt T, Brucker Sy, Kommos S, Heitz F, Welz J, Egger Ek, Kalder M, Buderath P, Klar M, Marth C, Ulrich Ua, Weigel M, Traub L, Anthuber C, Strauss H, Hanker L, Link T, Kubiak K, Melekian B, Hornung D, Pölcher M, Lampe B, Krauß T, Keilholz U, Flörcken A, Pietzner K, Sehouli J
Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)
Int J Gynecol Cancer 2023;33:223–230. doi:10.1136/ijgc-2022-003800
448. Kuehne F, Arvandi M, Hess LM, Faries DU, Matteucci Gothe R, Gothe H, Beyrer J, Zeimet AG, Stojkov I, Mühlberger N, Oberaigner W, Marth C, Siebert U,
Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: Systematic bias assessment of ovarian cancer treatment effectiveness
Journal of Clinical Epidemiology 2022, doi.org/10.1016/j.jclinepi.2022.10.005
447. Konstantinopoulos PA, Gonzalez-Martin A, Melo Cruz F, Friedlander M, Glasspool R, Lorusso D, Marth C, Monk BJ, Kim JW, Hinson P, Ajipa O, Pretre V, Han Y & Matulonis UA
EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Future Oncology 2022, doi.org 10.2217/fon-2022-0666, ISSN 1479-6694

446. Heinzl N, Koziel K, Maritschnegg E, Berger A, Pechriggl EJ, Zeimet AG, Marth C, Zeillinger R, Concin N
A comparison of four technologies for detecting p53 aggregates in ovarian cancer
Frontiers in Oncology 2022, doi.org/10.3389/fonc.2022.976725
445. Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz J-E, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA, on behalf of the participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Lancet Oncol 2022; 23: e374–84. doi.org/10.1016/S1470-2045(22)00139-5
444. Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH.
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
Cancer. 2022 Aug 15;128(16):3080-3089. doi: 10.1002/cncr.34350. Epub 2022 Jun 17. PMID: 35714310.
443. Oaknin A, Bosse TJ, Creutzber CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, Ledermann JA, Colombo N, ESMO Guidelines Committee
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
Annals of Oncology (2022), doi.org/10.1016/j.annonc.2022.05.009
442. McLaughlin PMJ, Klar M, Zwimpfer TA, Dutilh G, Vetter M, Marth C, du Bois A, Schade-Brittinger C, Reuss A, Bommer C, Kurzeder C, Heinzelmann-Schwarz V
Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial
BMC Cancer 22, 508 (2022). doi.org/10.1186/s12885-022-09555-8
441. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C,

- Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Radiotherapy and Oncology 154 (2022), doi.org/10.1016/j.radonc.2020.11.018
440. Vergote I., González-Martín A., Ray-Coquard I., Harter P., Colombo N., Pujol P., Lorusso D, Mirza MR., Brasiuniene B, Madry R, Brenton JD, Ausems MGEM, Büttner R & Lambrechts D, on behalf of the European experts' consensus group
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Annals of Oncology (2022) doi.org/10.1016/j.annonc.2021.11.013
439. Fiegl H, Hagenbuchner J, Kyvelidou C, Seeber B, Sopper S, Tsibulak I, Wieser V, Reiser E, Roessler J, Huhtinen K, Carpén O, Parson W, Sprung S, Marth C, Ausserlechner MJ, Zeimet AG.
Dubious effects of methadone as an “anticancer” drug on ovarian cancer cell-lines and patient-derived tumor-spheroids
Gynecol Oncol. 2022 Jan 12:S0090-8258(22)00009-9. doi: 10.1016/j.ygyno.2022.01.008.
438. Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio M.J, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Int J Gynecol Cancer 2021;0:1–8. doi:10.1136/ijgc-2021-003017
437. Concin N, Planchamp F, Abu-Rustum NR, Ataseven B, Cibula D, Fagotti A, Fotopoulou C, Knapp P, Marth C, Morice P, Querleu D, Sehouli J, Stepanyan A, Taskiran C, Vergote I, Wimberger P, Zapardiel I, Persson J
European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma
Int J Gynecol Cancer 2021; 0:1–22. doi:10.1136/ijgc-2021-003178
436. Vergote I, Ray-Coquard I, Anderson D. M, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez M, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P

- Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer**
European Journal of Cancer 157 (2021), doi: 10.1016/j.ejca.2021.08.023
435. Knoll K, Reiser E, Leitner K, Kögl J, Ebner C, Marth C, Tsibulak I
The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective
Archives of Gynecology and Obstetrics (2021) doi:10.1007/s00404-021-06259-5
434. Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, Neven P, Hitre E, Graas MP, Simoncini E, Abdi E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Gombos A, Ruhstaller T, Burstein HJ, Rabaglio M, Ruepp B, Ribí K, Viale G, Gelber RD, Coates A.S, Loi S, Goldhirsch A, Regan MM, Colleoni M, on behalf of the SOLE Investigators
Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
Annals of Oncology (2021), doi: 10.1016/j.annonc.2021.07.017.
433. Steinkasserer L, Irmgard D, Weiss T, Dirschlmaier W, Mossig M, Zeimet AG, Marth C.
Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data
Archives of Gynecology and Obstetrics (2021) doi:10.1007/s00404-021-06117-4
432. Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopolou C, Gonzalez Martin A, Lax SF Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturzda AE, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Virchows Arch (2021) doi:10.1007/s00428-03007-z
431. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopolou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturzda A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Int J Gynecol Cancer (2021) 1:12-39

430. Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerme E, Golmard L, Goardon N, Sevent N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I
Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial
J Natl Cancer Inst (2020) doi:10.1093/jnci/djaa193
429. Leitner K, Tsibulak I, Wieser V, Knoll K, Reimer D, Marth C, Fiegl H, Zeimet AG
Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
Sci Rep (2020) 10:20412
428. Tsibulak I, Wieser V, Welponer H, Leitner K, Hackl H, Marth C, Fiegl H, Zeimet AG
Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort
Acta Oncol (2021) 2:187-190
427. Tsibulak I, Reiser E, Bogner G, Petru E, Hell-Teutsch J, Reinthaller A, Weirather C, Weiss T, Bozsa S, Puschacher B, Hall M, Hittler D, Hrauda K, Thell E, Clauss S, Pozniak J, Aliche S, Gangl D, Gmperl G, Ebner C, Knoll K, Leitner K, Schilcher A, Schinnerl M, Sigl V, Singer C, Aigmüller T, Hofstätter B, Marth C
Decrease in gynecological cancer diagnosis during the COVID-19 pandemic: an Austrian perspective
Int J Gynecol Cancer (2020) 11:1667-1671
426. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churrua C, Boyd AP, Kristensen G, Glamp A, Ray-Coquard I, Vergote I
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian

Tube, or Primary Peritoneum

J Clin Oncol (2020) in press

425. Greggi S, Falcone F, Scaffa C, du Bois A, Samartzis EPP, Pujade-Lauraine E, Cibula D, Madry R, Korach J, Gungorduk K, McNeish IA, Zanagnolo V, Marth C, van Altena AM, Aravantinos G, Sehouli J, Vergote I, Gonzalez Martin A
Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey
Int J Gynecol Cancer (2020) pii:ijgc-2019-001172
424. Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommos S, du Bois A, Kurtz JE, AGO-OVAR 2.21/ENGOT-ov 18 Investigators
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Lancet Oncol (2020) 21:699-709
423. Wieser V, Abdel Azim S, Sprung S, Knoll K, Kögl J, Hackl H, Marth C, Zeimet AG, Fiegl H
TNF α signalling predicts poor prognosis of patients with endometrial cancer
Carcinogenesis (2020) Apr 6
422. Luger AK, Steinkohl F, Aginer F, Jaschke W, Marth C, Zeimet AG, Reimer D
Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer
Acta Obstet Gynecol Scand (2020) Feb 29
421. Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, Helfgott R, Marth C, Öhler L, Hubalek M, Lang A, Tinchon C, Haslbauer F, Redl A, Hock K, Hennebelle M, Mraz B, Gnant M
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy in routine

- clinical practice: Primary results from the non-interventional study, STEPAUT**
Breast (2020) 50:64-70
420. Welponer H, Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Marth C, Hackl H, Fiegl H, Zeimet AG
The miR-34 family and its clinical significance in ovarian cancer
J Cancer (2020) 11:1446-1456
419. Widschwendter A, Riedl D, Freidhager K, Abdel Azim S, Jerabek-Klestil S, D’Costa E, Fessler S, Ciresa-König A, Marth C, Böttcher B
Perception of Labial Size and Objective Measurements – Is There a Correlation? A Cross-Sectional Study in a Cohort Not Seeking Labiaplasty
J Sec Med (2020) 17:461-469
418. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martin A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Come P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P, PAOLA-1 Investigators
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
N Engl J Med (2019) 381:2416-2428
417. Wolf D, Fiegl H, Zeimet AG, Wieser V, Marth C, Sprung S, Sopper S, Hartmann G, Reimer D, Boesch M
High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome
Int J Cancer (2020) 146:2007-2018
416. Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Ovarian Cancer – A Study of the GANNET53 Consortium
Front Oncol (2019) 9:832
415. Tsibulak I, Zeimet AG, Marth C

- Hopes and failures in front-line ovarian cancer therapy**
Crit Rev Oncol Hematol (2019) 143:14-19
414. Canazei M, Pohl W, Weninger J, Bliem H, Weiss EM, Koch C, Berger A, Firulovic B, Marth C
Effects of adjustable dynamic bedroom lighting in a maternity ward
Journal of Environmental Psychology, Volume 62, 2019, Pages 59-66, ISSN 0272-4944,
<https://doi.org/10.1016/j.jenvp.2019.01.010>.
413. Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT) and the GOG Foundation, Inc.
Joint ENGOT and GOG Foundation requirements for trials with industry partners
Int J Gynecol Cancer (2019) Jul 18
412. Widschwendter A, Böttcher B, Riedl D, Coban S, Mutz-Dehbalaie I, Matteucci Gothe R, Ciresa-König A, Marth C, Fessler S
Recurrence of genital warts in pre-HPV vaccine era after laser treatment
Arch Gynecol Obstet (2019) doi.org/10.1007/s00404-019-05242-5
411. Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG
Clinical Impact of RANK Signalling in Ovarian Cancer
Cancers (Basel) (2019): Jun 8; 11(6)
410. Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet AG
Ovarian Cancer Stem Cell Heterogeneity
Adv Exp Med Biol (2019) 1139:201-221
409. Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk PJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Lancet Oncol (2019) 20:862-876

408. Bjelic-Radisic V, Singer C, Tamussino K, Kölbl H, Petru E, Volgger B, Polterauer S, Oppelt P, Sevelda P, Bogner G, Marth C; Austrian Gynecologic Oncology Working Group. **Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition: Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology**
Wien Klin Wochenschr (2019) 131:233-236
407. Degasper C, Brunner A, Sampson N, Tsibulak I, Wieser V, Welponer H, Marth C, Fiegl H, Zeimet AG
NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer
Tumour Biol (2019) 41(2):1010428319830002
406. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
N Engl J Med (2019) 380:822-832
405. Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mineritsch B, Exner R, Fesl C, Frantal S, Singer CF on behalf of the Austrian Breast and Colorectal Cancer Study Group
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABC SG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol (2019) 20:339-351
404. Wieser V, Tsibulak I, Degasper C, Welponer H, Leitner K, Parson W, Zeimet AG, Marth C, Fiegl H
Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer

- Cancer Science (2019) 110:1117-1126
403. Reich O, Braune G, Eppel W, Fiedler T, Graf A, Hefler L, Joura E, Kölbl H, Marth C, Pokieser W, Regitnig P, Reinthaller A, Tamussino K, Widschwendter A, Zeimet A, Kohlberger P
Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the diagnosis and treatment of cervical intraepithelial neoplasia and appropriate procedures when cytological specimens are unsatisfactory
Geburtshilfe Frauenheilkd (2018) 78:1232-1244
402. Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K
Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO – a focus on surgical aspects
Int J Gynecol Cancer (2019) 29:181-187
401. Marth C, Wieser V, Tsibulak I, Zeimet AG
Immunotherapy in ovarian cancer: fake news or the real deal?
Int J Gynecol Cancer (2019) 29:201-211
400. Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
Lancet Oncol (2018) 19:1680-1687
399. Marth C
Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study
Expert Rev Anticancer Ther (2018) 18 (supp 1):19-22
398. Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C,

- Fiegl H, Zeimet AG
BRCA1 und BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
Br J Cancer (2018) 119:683-692
397. Boesch M, Sopper S, Marth C, Fiegl H, Wiedemair A, Rössler J, Hatina J, Wolf D, Reimer D, Zeimet AG
Evaluation of Vav3.1 as prognostic marker in endometrial cancer
J Cancer Res Clin Oncol (2018) 144:2067-2076
396. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol (2018) 29 (Suppl. 4):iv262
395. Wieser V, Gaugg I, Fleischer M, Shivaingaiiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
Oncotarget (2018) 9:17501-17511
394. Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J
Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecological Oncology (NOGGO), AGO Austria and AGO Switzerland
Arch Gynecol Obstet (2018) 297:847
393. Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J
The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German “Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)”, the

- Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecological Oncology**
Arch Gynecol Obstet (2018) 297:837-846
392. Marth C, Reimer D, Zeimet AG
Front-line therapy of advanced epithelial ovarian cancer: standard treatment
Ann Oncol (2017) Nov 1; 28 (suppl_8):viii36-viii39
391. Reimer D, Bösch M, Wolf D, Marth C, Sopper S, Hatina J, Altevogt P, Parson W, Hackl H, Zeimet AG
Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response
Int J Cancer (2017) Dec 1
390. Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, gombos A, Ruhstaller T, Burstein H, Ribí K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicenter, open-label, randomized, phase 3 trial
Lancet Oncol (2017) Nov 17 pii: S1470-2045 (17) 30715-5
389. Poveda A, Marth C
Platinum or nonplatinum in recurrent ovarian cancer: that is the question
Future Oncol (2017) Oct 13(23s): 11-16
388. Poveda A, Marth C
Managing relapsed ovarian cancer in a rapidly evolving landscape
Future Oncol (2017) Oct 13(23s): 1
387. Jahn B, Arvandi M, Rochau U, Fiegl H, Goebel G, Marth C, Siebert U.
Development of a novel prognostic score for breast cancer patients using mRNA expression of *CHAC1*

- J Comparative Effectiveness Research (2017) 7:563-574
386. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N.
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol (2017) 28 (suppl 4): iv72-iv83
385. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
N Engl J Med (2017) 377:122-131
384. Zeimet AG, Mori H, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer C, Wimmer K, Zschocke J, Marth C
AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS)
Arch Gynecol Obstet (2017) 296:123-127
383. Oberaigner W, Geiger-Gritsch S, Edlinger M, Daniaux M, Knapp R, Hubalek M, Siebert U, Marth C, Buchberger W
Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria
Breast (2017) 33:178-182
382. Abdel Azim S, Sprung S, Mutz-Dehbalaie I, Fessler S, Zeimet AG, Marth C
L1CAM and HER2 expression in early endometrioid uterine cancer
Int J Gynecol Pathol (2017) 36:356-363
381. McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K
Fifth ovarian cancer consensus conference: individualized therapy and patient factors
Ann Oncol (2017) 28:702-710
380. Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I,

- Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N
Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients
Eur J Cancer (2016) 69:127-134
379. Potz FL, Tomasch G, Polterauer S, Laky R, Marth C, Tamussino K
Incidental (Prophylactic) Salpingectomy at Benign Gynecologic Surgery and Cesarean Section: a Survey of Practice in Austria
Geburtsh Frauenheilk (2016) 76:1325-1329
378. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Mueller-Holzner E, Marth C, Altevogt P, Zeimet AG
Regulation of the EGFR-E2F3a axis by the interferon regulatory factor (IRFS) and by promoter methylation of miR-34a in ovarian cancer
J Clin Oncol (2009) 27 (15suppl):e16522
377. Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus Trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Eur J Cancer (2016) 70:111-121
376. Dold C, Rodriguez Urbiola C, Wollmann G, Egerer L, Muik A, Bellmann L, Fiegl H, Marth C, Kimpel J von Laer D
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
Mol Ther Oncolytics (2016) 3:16021
375. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balsler JP, Agarwal S, Matulonis UA
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

NEJM (2016) Oct 7

374. Colombo N, Hardy-Bessard AC, Ferrandina G, Marth C, Romero I
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge
Expert Review of Anticancer Therapy (2016) Nov. 16 (sup 1): 11-19
373. Borena W, Grünberger M, Widschwendter A, Kraxner KH, Marth E, Mayr P, Meier J, Ruth N, guerrero AT, Marth C, Holm-von Laer D
Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.
BMC Public Health (201) Aug 26
372. Colleselli V, Nell T, Bartosik T, Brunner C, Ciresa-Koenig A, Wildt L, Marth C, Seeber B.
Marked improvement in the success rate of medical management of early pregnancy failure following the implementation of a novel institutional protocol and treatment guidelines: a follow-up study.
Arch Gynecol Obstet (2016) Aug 23
371. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD Bach BA, Oza AM
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Gynecol Oncol (2016) Aug 18
370. Pölsler L, Fiegl H, Wimmer K, Oberaigner W, Amberger A, Traunfellner P, Morscher RJ, Weber I, Fauth C, Wernstedt A, Sperner-Unterweger B, Oberguggenberger A, Hubalek M, Marth C, Zschocke J
High prevalence of *BRCA1* stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing
Eur J Human Genetics (2016) 24:258-262

369. Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A
European Society of Gynecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery
Int J Gynecol Cancer (2016) 26 (7): 1354-1363
368. Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rössler J, Marth C, Zeimet AG
Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers
BMC Cancer (2016) Aug 2
367. Volgger BM, Windbichler GH, Zeimet AG, Graf AH, Bogner G, Angleitner-Boubenizek L, Rohde M, Denison U, Sliutz G, Fuith LC, Fuchs D, Marth C
Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO)
Ann Oncol (2016) Jun 29
366. Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
J Clin Oncol (2016) 34(21):2516-2525
365. Notaro S, Reimer D, Duggan-Peer M, Fiegl H, Wiedemair A, Rössler J, Altevogt P, Marth C, Zeimet AG
Evaluating L1CAM expression in human endometrial cancer using qRT-PCR
Oncotarget (2016) 7(26):40221-40232
364. Abdel Azim S, Duggan-Peer M, Sprung S, Reimer D, Fiegl H, Soleiman A, Marth C, Zeimet AG

- Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer**
Oncotarget (2016) May 11
363. Harter P, du Bois A, Mahner S, Pfisterer J, Ortmann O, Marth C, Fink D, Hilpert F, Wagner U, Sehouli J. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland
Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
Geburtshilfe Frauenheilkunde (2016) 76(2):147-149
362. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidzinski M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjorge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Oncol 2016 (17)1:78-89
361. Schmid G, Notaro S, Reimer D, Abdel Azim S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin N, Altevogt P, Marth C, Zeimet AG
Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer
BMC Cancer (2016) 16(1):102
360. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Radiother Oncol (2015) 117(3):559-581

359. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Int J Gynecol Cancer (2016) 26(1):2-30
358. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Ann Oncol (2016) 27(1):16-41
357. Reich O, Regauer S, Marth C, Schmidt D, Horn LC, Dannecker C, Menton M, Beckmann MW
Systematik der präinvasiven Läsionen von Zervix, Vulva und Vagina nach der WHO-Klassifikation 2014 „Tumours of the Female Genital Tract“
Precancerous lesions of the cervix, vulva and vagina according to the 2014 WHO classification of tumors of the female genital tract
Geburtsh Frauenheilk (2015) 75(10):1018-1020
356. Petru E, Singer CF, Polterauer S, Galid A, Schauer C, Klocker J, Seifert M, Reinthaller A, Benedicic C, Hubalek M, Hefler L, Marth C, Scholl-Firon T, Bogner G, Zeimet AG
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: on oncologic expert statement
Wien Med Wochenschrift (2015) Oct 15
355. Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI
The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients – results from the OVCAD study
Tumour Biol (2015) Sep 29

354. van Dam PA, Tomatis M, Marotti L, Heil J, Wilson R, Rosselli Del Turco M, Mayr C, Costa A, Danei M, Denk A, Emons G, Friedrichs K, Harbeck N, Kiechle M, Koheler U, Kuemmel S, Maass N, Marth C, Prové A, Kimmig R, Rageth C, Regolo L, Salehi L, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Ponti A; eusomaDB Working Group;
The effect of EUSOMA certification on quality of breast cancer care
Eur J Surg Oncol (2015) 41(10):1423-1429
353. Early Breast Cancer Trialist's Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Lancet (2015) 386(10001):1353-1361
352. Early Breast Cancer Trialist's Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsy P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann b, van de Velde C, Pan H, Peto R, Davies C, Gray R.
Aromatase inhibitors versus tamoxifen in early breast cancer. patient-level meta-analysis of the randomised trials
Lancet (2015) 386(10001):1341-1352
351. Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG
AGO Austria recommendations for genetic testing of patients with ovarian cancer
Wien Klin Wochenschr (2015) 127 (15-16):652-654
350. Marth C, du Bois A, Schauer C, Casado A, Vergote I, Del Campo JM, Goudopoulou A, Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Chekerov R, Raza Mirza M, Westermann A, Glasspool r, Taskiran C, Fehr M, Cibula D
The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership
Int J Gynecol Cancer (2015) 25:1094-1095
349. du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J,

- Mirza M, Colombo N, Marth C, Witteveen E, Del Campo J, Calvert P, Aravantinos G, Vardar MA, van der Zee AG, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I; member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT)
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners – First Update 2015
Int J Gynecol Cancer (2015) 25:1328-1330
348. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF
Adjuvant denosumab in breast cancer (ABC SG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Lancet (2015) 386(9992): 433-443
347. Pölsler L, Fiegl H, Wimmer K, Oberaigner W, Amberger A, Traunfellner P, Morscher RJ, Weber I, Fauth C, Wernstedt A, Sperner-Unterweger B, Oberguggenberger A, Hubalek M, Marth C, Zschocke J
High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing
Eur J Hum Genet (2015) May 27 in press
346. Daniaux M, De Zordo T, Santner W, Amort B, Koppelstätter F, Jaschke W, Dromain C, Oberaigner W, Hubalek M, Marth C
Dual-energy contrast-enhanced spectral mammography (CESM)
Arch Gynecol Obstet (2015) in press
345. Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, Obermair A
Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance
BMC Cancer (2015) 15:33
344. Volgger B, Zeimet AG, Reinthaller A, Petru E, Schauer C, Klein M, Sevelda-Schwarzgruber U, Bogner G, Wolfram G, Marth C

- Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.**
Int J Gynecol Cancer (2015) 25:257-262
343. Vergote IB, Marth C, Coleman RL
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications
Cancer Metastasis Rev (2015) 34:41-52
342. Fotopoulou C, Kraetschell R, Dowdy S, Fujiwara K, Yaegashi N, Larusso D, Casado A, Mahner S, Herzog TJ, Kehoe S, Vergote I, Miller DS, Marth C, Fujii S, Sehouli J.
Surgical and systematic management of endometrial cancer: an international survey
Arch Gynecol Obstet (2014) 291:897-905
341. Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W, Angleitner-Boubenizek L, Brandt B, Chekerov R.
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study
Br J Cancer (2014) 111(8):1519-1525
340. du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
J Clin Oncol (2014) 32(30):3374-3382
339. Oberguggenberger A, Goebel G, Beer B, Oberacher H, Meraner V, Sztankay M, Sperner-Unterweger B, Zeimet AG, Marth C, Hubalek M, Holzner B
Getting the Whole Picture: Adding Patient-reported Outcomes to Adjuvant Endocrine Treatment Evaluation in Premenopausal Breast cancer Patients
Breast J (2014) 20:555-557
338. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-

- Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Lancet Oncol (2014) Jun 17
337. Muendlein A, Hubalek M, Geller-Rhomberg S, Gasser K, Winder T, Drexel H, Decker T, Mueller-Holzner E, Chamson M, Marth C, Lang AH
Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients
Eur J Cancer (2014) 50:2134-2141
336. EBCTCG (Early Breast Cancer Trialist's Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
Lancet (2014) 383:2127-2135
335. Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group
Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment
Int J Gynecol Cancer (2014) 24:468-477
334. Stadlmann S, Feichtinger H, Mikuz G, Marth C, Zeimet AG, Herold M, Knabbe C, Offner FA.
Interactions of Human Peritoneal Mesothelial Cells With Serous Ovarian Cancer Cell Spheroids-Evidence for a Mechanical and Paracrine Barrier Function of the Peritoneal Mesothelium
Int J Gynecol Cancer (2014) Jan 8 (pub ahead)

333. Bargehr J, Edlinger M, Hubalek M, Marth C, Reitsamer R
Axillary lymph node status in early-stage breast cancer patients with sentinel node micrometastase (0.2-2mm)
Breast Care (2013) 8:187-191
332. Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group and Gynecologic Cancer Intergroup Study
J Clin Oncol (2013) Dec 23 (pub ahead)
331. Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I; European Organization for Research and Treatment of Cancer – Gynaecological Cancer Group and NCIC Clinical Trials Group.
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
Gynecol Oncol (2013) 131:437-444
330. Peer M, Fellner W, Seeber BE, Zeimet AG, Marth C.
Endometrioid carcinoma developing in endometriosis over the symphysis pubis
Gynecologic Oncology Reports (2013) 6:45-46
329. Vergote I, Elser G, Votan B, Farrelly L, De Roover J, Bryce J, du Bois A; member trial groups of the European Network of Gynaecological Trial Groups (ENGOT)
Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials
Int J Gynecol Cancer (2013) 23:1339-1343
328. AGO, DGS, SGS, ÖGS; Panelists: Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, Gruber G, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F.
German, Austrian and Swiss consensus conference on the diagnosis and local

treatment of the axilla in breast cancer

Eur J Cancer (2013) 49:2277-2283

327. Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R, Taucher S, Wagener A, Marth C, Concin N.

Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial

Br J Cancer (2013) 9:215-218

326. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Abdel Azim S, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation

JNCI (2013) 105:1142-1150

325. Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, Kimmig R, Krawczyk N, Wallwiener D, Wimberger P, Kasimir-Bauer S

Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer

Int J Gynecol Cancer (2013) 23:839-845

324. Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J

Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD

Int J Gynecol Cancer (2013) 23:268-275

323. Ramoni A, Strobl EM, Tiechl J, Ritter M, Marth C

Conservative management of abnormally invasive placenta: four case reports.

Acta Obstet Gynecol Scand (2013) 92:468-471

322. Oberaigner W, Leitner H, Oberaigner K, Marth C, Pinzger G, Concin H, Steiner H, Hofmann H, Wagner T, Mörtl M, Ramoni A.
Migrants and obstetrics in Austria – applying a new questionnaire shows differences in obstetric care and outcome
Wiener Klin Wochenschrift (2013) 125:34-40
321. Lass-Flörl C, Mutschlechner W, Aigner M, Grif K, Marth C, Girschikofsky M, Grander W, Greil R, Russ G, Cerkl P, Eller M, Kropshofer G, Eschertzhuber S, Kathrein H, Schmid S, Beer R, Lorenz I, Theurl I, Nachbaur D.
Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study
J Clin Microbiol (2013) 51:863-868
320. Steffensen KD, Waldstrøm M, Pallisgård N, Lund B, Bergfeldt K, Wihl J, Keldsen N, Marth C, Vergote I, Jakobsen A.
Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study
Int J Gynecol Cancer (2013) 23:73-80
319. Mündlein A, et al.
Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer
J Cancer Res Clin Oncol (2012) Nov 23
318. Oberguggenberger AS, Sztankay M, Beer B, Schubert B, Meraner V, Oberacher H, Kemmler G, Giesinger J, Gamper E, Sperner-Unterweger B, Marth C, Holzner B, Hubalek M
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects
BMC Cancer (2012) 474
317. Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser C, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, Hatina J

Ovarian cancer stem cells

Neoplasma (2012) 747-755

316. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood m, Bonaventura T, Vergote I, Piccirillo MC, Fossati r, Gebski V, Lauraine EP
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
Br J Cancer (2012) 588-591
315. Polterauer S, Grimm C, Hofstetter G, Concin N, Natter C, Sturdza A, Pötter R, Marth C, Reinthaller A, Heinze G
Nomogram prediction for overall survival of patients diagnosed with cervical cancer
Br J Cancer (2012) 918-924
314. Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A
HE4 is an independent prognostic marker in endometrial cancer
Gynecol Oncol (2012) 186-191
313. Seebacher V, Polterauer S, Grimm C, Rahhal J, Hofstetter G, Bauer EM, Husslein H, Leipold H, Marth C, Reinthaller A, Concin N
Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial
Br J Cancer 2012 (106) 1551-1555
312. Schwab W, Marth C, Bergant AM
Post-traumatic stress disorder post partum
Gebursh Frauenheilk 2012 (72) 56-63
311. du Bois A, Marth C, Pfisterer J, Harter P, Hilpert F, Zeimet AG, Sehouli J
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer
Int J Gynecol Cancer 2012 (2) 182-185
310. Hofstetter G, Berger A, Berger R, Zoric A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet

- AG, Ulmer H, Moll U, Zeillinger R, Concin N
The N-Terminally truncated p53 isoform Δ 40p53 influences prognosis in mucinous ovarian cancer
Int J Gynecol Cancer 2012 (22) 372-379
309. van der Zee AG, Colombo N, Gitsch G, Reed N, Amant F, Cibula D, Kesic VI, Kimmig R, Lopes AD, Markowska J, Marth C, Radolakis A, Salvesen H, Vaitkiene D, Verheijen RH; Zola P
ESGO Statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer
Int J Gynecol Cancer 2012 (22) 175
308. Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, Roman LD, Berchuck A, Pearce CL, Laird PW
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer
PLoS One 2011 (6): 28141
307. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10.801 women in 17 randomised trials
Lancet 2011 (378) 1707-1716
306. Hofstetter G, Berger A, Chamson M, Müller-Holzner E, Reimer D, Ulmer H, Uramoto H, Marth C, Zeimet AG, Zeillinger R, Concin N
Clinical relevance of TAp73 and Δ Np73 protein expression in ovarian cancer: a series of 83 cases and review of the literature
Int J Gynecol Pathol 2011 (6) 527-531
305. Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu E, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N

- A 133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer***
Br J Cancer 2011 (105) 1593-1599
304. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Semsroth S, Zeimet AG, Marth C, Siegl H, Rieger K, Ulmer H, Concin H, Grob K
Evidence for cosmetics as potentially relevant sources of mineral oil contamination in women
J Womens Health 2011 (20) 1713-1719
303. Marth C, Zeimet A, du Bois A
Is neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery ?
Oncology 2011 (Sept) 942-944
302. Göbel G, Auer d, Gaugg I, Schneitter A, Lesche R, Müller-Holzner E, Marth C, Daxenbichler G
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients
Breast Cancer Res Treat 2011 (1) 109-117
301. Cibula D, Verheijen R, Lopes A, Amant F, Beller U, Colombo N, Gitsch G, kesic V, Kimmig R, Markowska J, Marth C, Reed N, Rodolakis A, Salvesen H, Vaitkiene D, van der Zee AG, Zola P.
Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology: European Society of Gynecological Oncology (ESGO) Statement
Ing J Gynecol Cancer 2011 (7) 1264-1265
300. Early Breast Cancer Trialists' Collaborative Group (EBCTCG9; Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials
Lancet 2011 (3478) 771-784

299. Braun S, Reimer D, Strobl I, Wieland U, Wiesbauer P, Müller-Holzner E, Fessler S, Scherer A, Marth C, Zeimet AG
Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report
J Med Case Reports 2011 (1) 316
298. Polterauer S, Hofstetter G, Grimm C, Rahhal J, Mailath-Pokorny M, Kohl M, Concin N, Tempfer C, Marth C, Reinthaller A.
Relevance of gamma-glutamyltransferase – a marker for apoptotic balance – in predicting tumor stage and prognosis in cervical cancer.
Gynecol Oncol. 2011 (Jun 9)
297. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsy P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M.
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial.
J Clin Oncol. 2011 (29) 2653-2659
296. Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC; and on behalf of the Gynecologic Cancer InterGroup.
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
Int J Gynecol Cancer. 2011 (4) 763-770
295. Stuart GC, Kitchener H, Bacon M, Dubois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E; on behalf of the participants of the 4th Ovarian Cancer Consensus Conference (OCCC).
2010 Gynecologic Cancer InterGroup (GCIIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference
Int J Gynecol Cancer. 2011(4) 750-755
294. Göbel G, Auer D, Gaugg I, Schneitter A, Lesche R, Müller-Holzner E, Marth C,

- Daxenbichler G
Prognostic significance of methylated *RASSF1A* and *PITX2* genes in blood- and bone marrow plasma of breast cancer patients
Breast Cancer Res Treat 2011 (Jan 8)
293. Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P, Zeimet AG
Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer
Oncogene 2011 (Apr 25)
292. Trimble EL, Fujiwara K, Marth C, Abrams J
Use of IP chemotherapy in ovarian cancer: the critical questions
Oncology 2011 (17) 173-174
291. Oberaigner W, Buchberger W, Frede T, Daniaux M, Knapp R, Marth C, Siebert U
Introduction of organized mammography screening in Tyrol: results of a one-year pilot phase
BMC Public Health 2011 (11) 91
290. Zeimet AG, Fiegl H, Goebel G, Kopp F, Allasia C, Reimer D, Steppan I, Müller-Holzner E, Ehrlich M, Marth C
DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer
Gynecologic Oncology 2011 (121) 24-31
289. Viswanathan AN, Creutzberg CL, Craighead P, McCormack M, Toita T, Narayan K, Reed N, Long H, Kim HJ, Marth C, Lindegaard JC, Cerrotta A, Small W Jr, Trimble E.
International Brachytherapy Practice Patterns: A Survey of the Gynecologic Cancer Intergroup (GCIG)
Int J Radiat Oncol Biol Phys. 2010 Dec 22
288. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC; Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N,

- Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L.
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, Mai 2009
Int J Gynecol Cancer. 2010 (20) 1290-1298
287. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S.
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast
J Natl Cancer Inst Monogr. 2010 (41) 162-177 (Review)
286. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group.
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
N Engl J Med. 2010 (363) 943-953
285. Petru E, Reinthaller A, Angleitner-Boubenizek L, Schauer C, Zeimet A, Dirschlmayer W, Medl M, Stummvoll W, Sevelde P, Marth C
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologist's expert meeting
Wien Klin Wochenschr 2010 (122) 649-652
284. Hubalek M, Brunner C, Matthä K, Marth C
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment
Wien Med Wochenschr 2010 (Oct 26)
283. Volgger B, Kurz K, Zöschg K, Theurl I, Ciresa-König A, Marth C
Importance of erythropoietin receptor expression in tumour tissue for the clinical course of breast cancer
Anticancer Res 2010 (9) 3721-3726

282. Zeimet AG, Reimer D, Schwentner L, Fuchs D, Wolf D, Fuith LC, Fiegl H, Doppler W, Concin N, Daxenbichler G, Marth C
Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer
Cancer Immunol Immunother 2010 (12) 1813-1823
281. Wolf AM, Rumpold H, Reimer D, Marth C, Zeimet AG, Wolf D
High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer
Gynecol Oncol 2010 (118) 244-250
280. Hubalek M, Brantner C, Marth C.
Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
Wien Med Wochenschr 2010 (160) 167-173
279. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG.
E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer
Cancer Res 2010 (11) 4613-4623
278. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L.
A genomic index of sensitivity to endocrine therapy for breast cancer
J Clin Oncol 2010 (27) 4111-4119
277. Scheier M, Peter M, Hager C, Lang T, Barvinek A, Marth C
Spontaneous isolated midtrimester fracture of tibia and fibula in a normal fetus with in utero healing and good long-term outcome
Fetal Diagn Ther 2010 (11) 58-60
276. Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P,

- Bamias A, Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies
Int J Gynecol Cancer 2010 (20) 476-478
275. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird PW, Jacobs IJ, Widschwendter M
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer
Genome Res 2010 (4) 440-446
274. Oberaigner W, Buchberger W, Frede T, Knapp R, Marth C, Siebert U
Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening
BMC Public Health 2010 (10)
273. Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, Marth C, Zeimet AG, Concin N, Zeillinger R
Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer
Oncogene 2010 (13) 1997-2004
272. Steppan I, Reimer D, Müller-Holzner E, Marth C, Aigner F, Frauscher F, Frede T, Zeimet AG
Breast cancer in women: evaluation of benign and malignant axillary lymph nodes with contrast-enhanced ultrasound
Ultraschall Med 2010 (1) 63-67
271. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, Edler L, Münch M, Müller-Holzner E, Jerabek-Klestil S, Abdel-Azim S, Marth C, Zeimet AG, Altevoigt P, Fogel M
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in

- aggressive subtypes of endometrial carcinomas**
J Pathol 2010 (5) 551-561
270. Steppan I, Reimer D, Sevelde U, Ulmer H, Marth C, Zeimet AG
Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin – an evaluation of the therapeutic index with special emphasis on cardiac toxicity
Chemotherapy 2009 (6) 391-398
269. Müller KP, Erdel F, Caudron-Herger M, Marth C, Fodor BD, Richter M, Scaranaro M, Beaudouin J, Wachsmuth M, Rippe K.
Multiscale analysis of dynamics and interactions of heterochromatin protein 1 by fluorescence fluctuation microscopy.
Biophys J 2009 (11) 2876-2885
268. Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study
Oncologist 2009 (10) 979-985
267. Breast Cancer Association Consortium
Risk of estrogen receptor-positive and –negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042
J Natl Cancer Inst 2009 (101) 1012-1018
266. Zeimet AG, Reimer D, Radl AC, Reinthaller A, Schauer C, Petru E, Concin N, Braun S, Marth C
Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer
Anticancer Res 2009 (29) 2803-2808
265. Braun S, Auer D, Marth C
The prognostic impact of bone marrow micrometastases in women with breast cancer
Cancer Invest 2009 (27) 598-603

264. Gnant M, Dubsy P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Rücklinger E, Jakesz R, Greil R für die ABCSG
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit ?
Clinical Breast Cancer 2009 (9) Suppl. 1, S18-S27
263. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW, LIBERATE Study Group
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non inferiority trial
Lancet Oncol 2009 (10) 135-146
262. Gnant M, Mlineritsch B, Schippinger W, Lusch-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsy P, Fridrik M, Fitzal f, Stierer M, Rücklinger E, Greil R, ABCSG-12 Trial Investigators, Marth C
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
N Engl J Med 2009 (360) 679-691
261. Marth C, Hiebl S, Oberaigner W, Winter R, Leodolter S, Sevela P
Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology
Int J Gynecol Cancer 2009 (19) 94-102
260. Kitchener HC, Trimble EL, Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup
Endometrial cancer state of the science meeting
Int J Gynecol Cancer 2009 (19) 134-140
259. Volgger B, Petru E, Angleitner-Boubenizek L, Weigert M, Reinthaller A, Lass H, Stempf A, Gamper C, Deibl M, Marth C
Erythropoetin β twice weekly versus standard therapy in patients with gynaecological

- malignancies – a randomised austrian AGO trial**
Anticancer Res 2008 (28) 3977-3984
258. Zeimet AG, Reimer D, Wolf D, Fiegl H, Concin N, Wiedemair A, Wolf AM, Rumpold H, Müller-Holzner E, Marth C
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer
Int J Cancer 2008, Dec. 15
257. Klotz R, Zeimet AG, Reimer D, Müller-Holzner E, Chamson M, Marth C
Activated p38-MAPK and gemcitabine sensitivity in recurrent ovarian cancer
Anticancer Res 2008 (28) 2975-2980
256. Scheier M, Ramoni A, Alge A, Brezinka C, Reiter G, Sergi C, Hager J, Marth C
Congenital Fibrosarcoma as Cause for Fetal Anemia: Prenatal Diagnosis and in utero Treatment
Fetal Diagn Ther 2008 (24) 434-436
255. Hofstetter G, Concin N, Marth C, Rinne T, Erdel M, Janecke A
Genetic analyses in a variant of Mayer-Rokitansky-Kuster-Hauser syndrome (MURCS association)
Wien Klin Wochenschr 2008 (120) 435-439
254. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsy P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSCG)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSCG-12 bone-mineral density substudy.
Lancet Oncol 2008 (9) 840-849
253. Egle D, Grisseemann B, Zeimet AG, Müller-Holzner E, Marth C
Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinoma

- Gynecol Oncol 2008 (110) 286-292
252. Auer D, Reimer D, Porto V, Fleischer M, Roessler J, Wiedemair A, Marth C, Müller-Holzner E, Daxenbichler G, Zeimet AG
Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer
Breast Cancer Res Treat 2008 (Jul 10)
251. Reimer D, Sztankay A, Steppan I, Abfalter E, Lunzer H, Marth C, Zeimet AG
Cervical cancer associated with genital prolapse- a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient.
Eur J Gynaecol Oncol 2008 (29) 272-275
250. Bener C, Marth C
Adjuvante Therapie des Mammakarzinoms mit Trastuzumab
Gynäkol Geburtshilfliche Rundschau 2008 (48) 138-142
249. Seeber J, Sepp N, Spizzo G, Wiesbauer P, Reimer D, Marth C, Zeimet AG
Pure multivisceral manifestation of paraneoplastic dermatomyositis mimicked highly disseminated recurrent carcinoma of the fallopian tube.
J Eur Acad Dermatol Venerol 2008 (229) 756-757
248. Seeber J, Reimer D, Müller-Holzner E, Spizzo G, Sepp N, Wiesbauer P, Marth C, Zeimet AG
Fallopian tube cancer associated with paraneoplastic dermatomyositis – asymptomatic multivisceral exacerbated dermatomyositis mimicking recurrent widespread malignant disease: case report.
Eur J Gynaecol Oncol 2008 (29) 168-170
247. Alberts DS, Marth C, Alvarez RA, Johnson G, Bidzinski M, Kardatzke DR, Williamson BZ, Loutit J, Kim DH, Clouser MC, Markman M
Randomized phase 3 trial of interferon-gamm-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively

designed analysis of progression-free survival

Gynecologic Oncology 2008 (109) 174-181

246. Kautzky-Willer A, Bancher-Todesca D, Weitgasser R, Prikoszovich T, Steiner H, Shnawa N, Scherthaner G, Birnbacher R, Schneider B, Marth C, Roden M, Lechleitner M
The impact of risk factors and more stringent diagnostic criteria of gestational diabetes on outcomes in central European women.
J Clin Endocrinol Metab 2008 (93) 1689-16995
245. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.
Clin Cancer Res 2008 (14) 710-714
244. Volgger B, Aspisirengil C, Genser-Krimbacher E, Ciresa-Koenig A, Daxenbichler G, Fuchs D, Windbichler G, Marth C
Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix
Cancer Lett 2008 (262) 183-189
243. Early Breast Cancer Trialist's Collaborative Group (EBCTCG)
Adjuvant polychemotherapy in oestrogen-receptor-poor breast cancer: meta-analysis of individual patient data from the randomised trials
Lancet 2008 (371) 29-40
242. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dofou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Z MR, Hansson J, Egyhazi S, Petrsson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C.
FBXW7/hCDC4 is a General Tumor Suppressor in Human Cancer
Cancer Res 2007 (67) 9006-9012
241. Salani R, Davidson B, Fiegl M, Marth C
Measurement of cyclin E genomic copy number and strand length in cell-free DNA

distinguish malignant versus benign effusions

Clin Cancer Res 2007 (13) 5805-5809

240. Braun S, Vogl FD, Schneitter A, Egle D, Auer D, Lang M, Marth C
Disseminated tumor cells: are they ready for clinical use ?
Breast 2007 (16) Suppl.2, 51-54
239. Wolf AM, Rumpold H, Wolf D, Gastl G, Reimer D, Jenewein N, Marth C, Zeimet AG
Role of forkhead box protein 3 expression in invasive breast cancer
J Clin Oncol 2007 (25) 4499-4500
238. Haffner MC, Petridou B, Peyrat JP, Revillion F, Muller-Holzner E, Daxenbichler G, Marth C, Doppler W
Favorable prognostic value of SOCS2 and IGF-I in breast cancer
BMC Cancer 2007 (7) 136
237. Scheier M, Egle D, Himmel I, Ramoni A, Viertl S, Huter O, Marth C
Impact of nuchal cord on measurement of fetal nuchal translucency thickness
Ultrasound Obstet Gynecol 2007 (Jun 15)
236. Hubalek M, Smekal-Schindelwig C, Zeimet AG, Sergi C, Brezinka C, Mueller-Holzner E, Marth C.
Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma
Arch Gynecol Obstet (2007) March 7
235. Marth C, Egle D, Auer D, Rossler J, Zeimet AG, Vergote I, Daxenbichler G.
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab
Gynecol Oncol 105 (2007) 716-721
234. Mueller-Holzner E, Frede T, Daniaux M, Ban m, Taucher S, Schneitter A, Zeimet AG, Marth C
Ultrasound-guided core needle biopsy of the breast: does frozen section give an accurate diagnosis ?
Breast Cancer Res Treat (2007) Feb 21

233. Marth C, Walker JL Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Trope C, Wenzel L, Zeimet AG
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer
Cancer 109 (2007) 645-649
232. Shih Ie-M, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Muller-Holzner E, Gastl G, Zhang Z, Diamandis EP.
Ovarian cancer specific kallikrein profile in effusions
Gynecol Oncol 105 (2007) 501-507
231. Reimer D, Steppan I, Wiedemair A, Concin N, Hofstetter G, Marth C, Mueller-Holzner E, Zeimet AG.
Soluble isoforms but not the transmembrane form of coxsackie-adenovirus receptor are of clinical relevance in epithelial ovarian cancer
Int J Cancer 120 (2007) 2568-2575
230. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Mueller-Holzner E, Marth C, Zeimet AG
Clinical relevance of E2F family members in ovarian cancer – an evaluation in a training set of 77 patients
Clin Cancer Res 13 (2007) 144-151
229. Fehm T, Müller V, Janni W, Braun S, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Pantel K, Solomayer E.
Konsensusempfehlungen zu methodischen Aspekten und zur klinischen Relevanz des Nachweises disseminierter Tumorzellen (DTZ) im Knochenmark (KM) von Patientinnen mit primärem Mammakarzinom
Geburtsh Frauenheilk 67 (2007) 329-335
228. Widschwendter A, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW
Epigenetic stem cell signature in cancer
Nat Genet 39 (2007) 157-158

227. Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G, Marth C, Zeimet AG
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer
Ann NY Acad Sci 1091 (2006) 270-281
226. Spruck C, Sun D, Fiegl H, Marth C, Mueller-Holzner E, Goebel G, Widschwendter M, Reed SI
Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer
Cancer Res 14 (2006) 7355-7360
225. Marth C, Beckmann M
Geburtshilfe und Frauenheilkunde ist wissenschaftliches Organ der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe
Geburtsh Frauenheilk 66 (2006) 641-642
224. Rieder J, Marth C, Hoffmann G
Effect of Neopterin Derivates on Mitochondrial Dehydrogenase Activity in Ovarian Carcinoma Cell Lines in Vitro
Pteridines 17 (2006) 115-120
223. Berger J, Mueller-Holzner E, Fiegl H, Marth C, Daxenbichler G.
Evaluation of three mRNA markers for the detection of lymph node metastases
Anticancer Research 26 (2006) 3855-3860
222. Marth C, Frede T, Müller-Holzner E, Taucher S, Daxenbichler G, Virgolini I, Gastl G, Lukas P, Schöller T, Wechselberger G, zur Nedden D
Brustgesundheitszentrum Tirol, Universitätskliniken, Innsbruck
Breast Care (2006) 336-337
221. Reimer D, Sadr S, Wiedemair A, Concin N, Hofstetter G, Marth C, Zeimet AG
Heterogenous cross-talk in E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF
Cancer Biol Ther 7 (2006) 771-776

220. Spizzo G, Went P, Dirnhofner S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer
Gynecol Oncol 103 (2006) 483-488
219. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E.
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.
Cancer 107 (2006) 885-892
218. Wolf D, Marth C, Wolf AM
Immune cells in colorectal cancer
N Engl J Med 354 (2006) 1531-1532
217. Fehm T, Müller V, Janni W, Braun S, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Pantel K, Solomayer E.
Konsensusempfehlungen zu methodischen Aspekten und zur klinischen Relevanz des Nachweises disseminierter Tumorzellen (DTZ) im Knochenmark (KM) von Patientinnen mit primärem Mammakarzinom.
Senologie 3 (2006) 114 – 120
216. Schwendinger V, Müller-Holzner E, Zeimet AG, Marth C.
Sentinel node detection with the blue dye technique in early cervical cancer
Eur J Gynaecol Oncol 27 (2006) 359 - 362
215. Marth C, Windbichler GH, Hausmaninger H, Petru E, Estermann K, Pelzer A, Mueller-Holzner E
Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study.
Int J Gynecol Cancer 16 (2006) 1522 – 1528

214. Petru E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet AG, Volgger B, Stempf A, Marth C.
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and –resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO study.
Gynecol Oncol 102 (2006) 226 – 229
213. Schneitter A, Auer D, Sevelde U, Marth C, Braun S
Bone marrow micrometastasis in breast cancer: a pooled analysis
The American Journal of Oncology Review 5 (2006) 2 – 7
212. Koelle D, Windisch J, Doerfler D, Marth C, Kropshofer S
Effect of tension-free vaginal tape operation on urethral closure function
Urology 67 (2006) 524-528
211. Fiegl H, Millinger S, Goebel G, Muller-Holzner E, Marth C, Laird PW, Widschwendter M.
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer
Cancer Res 66 (2006) 29-33
210. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo
Clin Cancer Res 23 (2005) 8372-8383
209. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K.
A pooled analysis of bone marrow micrometastasis in breast cancer
NEJM 353 (2005) 793-802
208. Widschwendter A, Brunhuber T, Wiedemair A, Mueller-Holzner E, Marth C

Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history

J Clin Virol 31 (2004) 292-297

207. Hubalek M, Ramoni A, Mueller-Holzner E, Marth C
Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer
Gynecol Oncol 95 (2004) 264-266
206. Widschwendter A, Gatringer C, Ivarsson L, Fiegl H, Schneitter A, Ramoni A, Muller HM, Wiedemair A, Jerabek S, Muller-Holzner E, Goebel G, Marth C, Widschwendter M.
Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors.
Clin Cancer Res 10 (2004) 3396-3400
205. Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, Mueller-Holzner E, Marth C.
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer
Gynecol Oncol 93 (2004) 407-416
204. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM
Transdominant Delta Tap73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo
Cancer Res 64 (2004) 2449-2460
203. Petru E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet AG, Volgger B, Stempf A, Marth C
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and –resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO study.
Gynecol Oncol (2006) 102:226-229
202. Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G
Dysregulated monocyte iron homeostasis and erythropoietin formation in patients

with anemia of chronic disease

Blood 107 (2006) 4142-4148

201. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Mueller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C
The expression of the regulatory T Cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
Clinical Cancer Research 11 (2005) 8326-8331
200. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M.
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients
Cancer Res 65 (2005) 1141-1145
199. Muller HM, Millinger S, Fiegl H, Goebel G, Ivarsson L, Widschwendter A, Müller-Holzner E, Marth C, Widschwendter M
Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool.
Clinical Chemistry 50 (2004) 2171-2173
198. Braun S, Marth C
Circulating tumor cells in metastatic breast cancer – toward individualized treatment?
N Engl J Med 351 (2004) 824-826
197. Marth C, Fiegl H, Zeimet AG, Müller-Holzner E, Deibl M, Doppler W, Daxenbichler G
Interferon- γ expression is an independent prognostic factor in ovarian cancer
Am J Obstet Gynecol 191 (2004) 1598-1605
196. Widschwendter M, Jiang G, Woods C, Müller HM, Fiegl H, Goebel G, Marth C, Müller-Holzner E, Zeimet AG, Laird PW, Ehrlich M
DNA hypomethylation and ovarian cancer biology
Cancer Research 64 (2004) 4472-4480

195. Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA, Laird PW
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.
Cancer Research 64 (2004) 3807-3813
194. Widschwendter A, Ivarsson L, Blassnig A, Müller HM, Fiegl H, Wiedemair A, Müller-Holzner E, Goebel G, Marth C, Widschwendter M
CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients
Int J Cancer 109 (2004) 163-166
193. Widschwendter A, Müller HM, Fiegl H, Ivarsson L, Wiedemair A, Müller-Holzner E, Goebel G, Marth C, Widschwendter M
DNA methylation in serum and tumors of cervical cancer patients
Clinical Cancer Research 10 (2004) 565-571
192. Widschwendter A, Blassnig A, Wiedemair A, Müller-Holzner E, Müller HM, Marth C,
Human papillomavirus DNA in sera of cervical cancer patients as tumor marker
Cancer Letters 202 (2003) 231-239
191. Müller HM, Widschwendter A, Fiegl H, Goebel G, Wiedemair A, Müller-Holzner E, Marth C, Widschwendter M
A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer
Cancer Letters 209 (2004) 231-236
190. Müller HM, Ivarsson L, Schröcksnadel H, Fiegl H, Widschwendter A, Goebel G, Kilgannogler S, Philadelphia H, Gütter W, Marth C, Widschwendter M
DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients
Clinical Chemistry 50 (2004) 1065-1068
189. Müller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M

- DNA methylation in serum of breast cancer patients: an independent prognostic marker**
Cancer Research 63 (2003) 7641-7645
188. Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl H, Müller HM, Goebel G, Müller-Holzner E, Marth C, Spruck CH, Reed SI, Widschwendter M
Cyclin E dysregulation and chromosomal instability in endometrial cancer
Oncogene (2004) 1-6
187. Fiegl M, Gatringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, Gaugg I, Goebel G, Müller HM, Müller-Holzner E, Marth C.
Methylated DNA collected by tampons – a new tool to detect endometrial cancer.
Cancer Epidemiol Biomarkers Prev 13 (2004) 882-888
186. Fiegl M, Haun M, Massoner A, Krugmann J, Müller-Holzner E, Hack R, Hilbe W, Marth C, Duba H.C., Gastl G, Grünewald K,
Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions
J Clin Oncol 22 (2004) 474-483
185. Braun S, Vogl FD, Janni W, Marth C, Schlimok, Pantel K
Evaluation of bone marrow in breast cancer patients: prediction of clinical outcome and response to therapy
The Breast 12 (2003) 397-404
184. Grünewald K, Haun M, Fiegl M, Gastl G, Marth C, Frede T
Blood dissemination of mammaglobin-specific RNA during core needle biopsy in patients with invasive breast carcinoma (Letter)
The Breast Journal 10 (2004) 61-62
183. Müller H, Fiegl H, Goebel G, Hubalek MM, Widschwendter A, Müller-Holzner E, Marth C, Widschwendter M
MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status

- Br J Cancer 89 (2003) 1934-1939
182. Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C, Illmensee K
Calgranulins in cystic fluid and serum from patients with ovarian carcinomas
Cancer Research 63 (2003) 7507-7514
181. Zeimet AG, Marth C
Why did p53 gene therapy fail in ovarian cancer?
Lancet Oncology 4 (2003) 19-26
180. Concin N, Hefler L, van Bavel J, Mueller-Holzner E, Zeimet A, Daxenbichler G, Speiser P, Hacker N, Marth C.
Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases
Gynecol Oncol 89 (2003) 9-15
179. Aapro MS, Van Wijk FH, Bolis G, Chevallier B, Van der Burg ME, Poveda A, De Oliveira CF, Tumolo S, Scotto Di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, Ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, Vermorken JB.
Doxorubicin versus docorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
Ann Oncol 14 (2003) 441-448
178. Schwärzler P, Fessler S, Marth C,
Robot-assisted laparoscopic surgery in gynaecology: first experiences and review of the literature
Eur Surg 34 (2002) 180-182
177. Ott HW, Illmensee K, Zeimet A, Müller-Holzner E, Windbichler G, Eibl G, Marth C
Die Wertigkeit der Second-Look-Operation bei Patientinnen mit einem Ovarialkarzinom oder Tubenkarzinom mittels einer retrospektiven Vergleichsstudie

Gynäkol Geburtsh Rundsch 42 (2002) 217-224

176. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer
Clin Cancer Res 8 (2002) 3065-3074
175. Gruenewald K, Haun M, Fiegl M, Urbanek M, Mueller-Holzner E, Massoner A, Riha K, Probst A, Marth C, Gastl G
Mammaglobin expression in gynecologic malignancies and malignant effusions detected by nested reverse transcriptase-polymerase chain reaction
Lab Invest 82 (2002) 1147-1153
174. Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, Muller-Holzner E, Marth C, Widschwendter M, Reed SI
hCDC4 gene mutations in endometrial cancer
Cancer Res 15 (2002) 4535-4539
173. Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger J, Hermann M, Widschwendter M, Bergelson JM, Marth C
Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinoma
Gene Ther 9 (2002) 1093-1100
172. Heim K, Widschwendter A, Pirschner G, Wieland U, Awerkiew S, Christensen ND, Bergant A, Marth C, Hopfl R
Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer
Am J Obstet Gynecol 186 (2002) 705-711
171. Widschwendter A, Riha K, Duba HC, Kreczy A, Marth C, Schwarzler P
Prenatal diagnosis of de novo mosaic deletion 13q associated with multiple abnormalities
Ultrasound Obstet Gynecol 19 (2002) 396-399

170. Marth C, Høifødt H, Walberg L, Kærn J, Mathiese O, Andresen M, Tropé C, Fodstad Ø
Detection of circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian cancer
in press
169. Marth C, Kisic J, Kærn Janne, Tropé C, Fodstad Ø
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
Cancer 94 (2002) 707 – 712
168. Amann A, Rieder J, Fleischer M, Niedermuller P, Hoffmann G, Amberger A, Marth C, Nigrovic V, Puhlinger F
The influence of atracurium, cisatracurium and mivacurium on the proliferation of two human cell lines in vitro
Anesth Analg 93 (2001) 690-696
167. Koelle D, Stenzl A, Koelbl H, Marth C.
Treatment of postoperative urinary retention by elongation of tension-free vaginal tape
Am J Obstet Gynecol 185 (2001) 250-251
166. Weiss HG, Nehoda H, Labeck B, Hourmont K, Marth C, Aigner F
Pregnancies after adjustable gastric banding.
Obes Surg 11 (2001) 303-306
165. Rieder J, Amann A, Schlösser M, Czechowski M, Seibel M, Marth C, Hoffmann G
Suppressive effects of neopterin in inducible nitric oxide synthase gene expression in ovarian carcinoma cells *in vitro*
Pteridines 12 (2001) 140 – 146
164. Rieder J, Jahnke R, Schloesser M, Seibel M, Czechowski M, Marth C, Hoffmann G.
Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines.
Gynecol Oncol 82 (2001) 172-176
163. Mueller-Holzner E, Fink V, Frede T, Marth C

- Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor**
Breast Cancer Res Treat 69 (2001) 13-19 2.866
162. Wagenaar HC, Pecorelli S, Vergote I, Curran D, Wagener D, Kobierska A, Bolis G, ten Bokkel-Huinink W, Lacave AJ, Madronal C, Forni M, de Oliveira, Mangioni C, Nooij MA, Goupil A, Kerbrat P, Marth Ch, Tumolo S, Herben MG, Zanaboni F, Vermorken JB
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma
Eur J Gynaecol Oncol (2001) 187-193
161. Widschwendter M, Berger J, Müller H, Zeimet AG, Marth C
Epigenetic downregulation of the retinoic acid receptor- β 2 gene in breast cancer
J Mammary Gland Biol Neoplasia 6 (2001) 193-201
160. Zeimet AG, Stadlmann S, Natoli C, Widschwendter M, Hermann M, Abendstein B, Daxenbichler G, Offner FA, Jacobelli S, Marth C
Peritoneal mesothelial cells as a significant source of ascitic immunostimulatory protein 90k
Anticancer Res 20 (2000) 4507-4512
159. Tropé C, Marth C, Kaern J
Tamoxifen in the treatment of recurrent ovarian carcinoma
Eur J Cancer 36 (2000) S59-S67
158. Rieder J, Marth C, Totzke G, Smolny M, Seibel M, Hoffmann G
Different patterns of inducible nitric oxide synthase gene expression in ovarian carcinoma cell lines
Anticancer Res 20 (2000) 3251-3258
157. Zeimet AG, Riha K, Berger J, Widschwendter M, Hermann A, Daxenbichler G, Marth C
New insights into p53 regulation and gene therapy for cancer
Biochem Pharmacol 60 (2000) 1153-1163

156. Grünewald K, Haun M, Urbanek M, Fiegl M, Müller-Holzner E, Gunsilius E, Dünser M, Marth C, Gastl G
Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19
Lab Invest 80 (2000) 1071-1077
155. Abendstein B, Stadlmann S, Knabbe C, Buck M, Müller-Holzner E, Zeimet AG, Marth C, Obrist P, Krugmann J, Offner FA
Regulation of transforming growth factor- β secretion by human peritoneal mesothelial and ovarian carcinoma cells
Cytokine 12 (2000) 1115-1119
154. Berger J, Telser A, Widschwendter M, Müller-Holzner E, Daxenbichler G, Marth C, Zeimet AG
Expression of retinoic acid receptors in non-neoplastic epithelial disorders of the vulva and normal vulvar skin
Int J Gynecol Pathol 19 (2000) 95-102
153. Abendstein B, Daxenbichler G, Windbichler G, Zeimet AG, Geurts A, Sweep F, Marth C
Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients
Anticancer Res 20 (2000) 569-572
152. Abendstein B, Marth C, Müller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG
Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma
Cancer 88 (2000) 1432-1437
151. Widschwendter M, Berger J, Hermann M, Müller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C
Methylation and silencing of the retinoic acid receptor- β 2 gene in breast cancer
J Natl Cancer Inst 92 (2000) 826-832

150. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Br J Cancer 82 (2000) 1138-1144
149. Paulsen T, Marth C, Kærn J, Nustad K, Kristensen GB, Tropé C
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol 76 (2000) 326-330
148. Cronauer MV, Stadlmann S, Klocker H, Abendstein B, Eder IE, Rogatsch H, Zeimet AG, Marth C, Offner FA
Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells
Am J Pathol 155 (1999) 1977-1984
147. Lechner W, Schröcksnadel H, Heim K, Daxenbichler G, Marth C
Induction of uterine contractions by Tumor Necrosis Factor- α
Eur J Infectious Diseases in Obstetrics and Gynecology 3 (1999) 67 - 71
146. Widschwendter M, Hermann M, Niescher M, Marth C, Zeimet AG
Smoking in pregnancy
Lancet 354 (1999) 1390 (Letter)
145. Tropé CG, Marth C, Scheistrøen M, Abeler VM
Endometriehyperplasi – diagnose og behandling
Tidsskr Nor Lægeforen 38 (1999) 517-520
144. Windbichler GH, Müller-Holzner E, Nicolussi-Leck G, Meisel U, Dapunt O, Marth C
Ovarian preservation in the surgical treatment of cervical carcinoma
Am J Obstet Gynecol 180 (1999) 963-969
143. Krimbacher E, Zeimet AG, Marth C, Kostron H
Photodynamic therapy for recurrent gynecologic malignancy:

- a report on 4 cases**
Arch Gynecol Obstet 262 (1999)193-197
142. Marth C, Sundfor K, Kaern J, Tropé C
Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous carcinoma of the cervix
Acta Oncol 38 (1999) 517-520
141. Zeimet AG, Widschwendter M, Hermann M, Müller-Holzner E, Daxenbichler G, Marth C
Interleukin-12 heterodimer in the ascitic fluid of patients with ovarian cancer
Int J Gynecol Cancer 9 (1999) 86
140. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
Cancer 85 (1999) 178-187
139. Marth C, Zeimet AG, Widschwendter M, Daxenbichler G
Regulation of CA-125 expression in cultured human carcinoma cells
Int J Biol Markers 13 (1998) 207-209
138. Widschwendter M, Widschwendter A, Welte T, Daxenbichler G, Zeimet AG, Bergant A, Berger J, Peyrat JP, Michel S, Doppler W, Marth C
Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro
Br J Cancer 79 (1999) 204-210
137. Uhl-Steidl M, Huy VQ, Müller-Holzner E, Ruth N, AG Zeimet, R Stauder, Daxenbichler G, Marth C
CD44 splice variant expression in normal and malignant uterine cervical epithelium
Int J Gynecol Cancer 8 (1998) 460-466

136. Moncayo HE, Penz-Koza A, Marth C, Gastl G, Herold M, Moncayo R
Vascular endothelial growth factor in serum and in the follicular fluid of patients undergoing hormonal stimulation for in-vitro fertilization
Hum Reprod 13 (1998) 3310-3314
135. Lechner W, Bergant A, Marth C, Kirchler H, Zwierzina H
Der Einfluß von Interleukin-6 auf die uterine Kontraktilität beim Menschen in vivo
Z Geburtsh Neonatol 202 (1998) 10-13
134. Zeimet AG, Offner FA, Müller-Holzner E, Widschwendter M, Abendstein B, Fuith LC, Daxenbichler G, Marth C
Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125
Tumor Biol 19 (1998) 275-282
133. Meister B, Fink FM, Hittmair A, Marth C, Widschwendter M
Antiproliferative activity and apoptosis induced by retinoic acid receptor- γ selectively binding retinoids in neuroblastoma
Anticancer Res 18 (1998) 1777-1786
132. Marth C, Tropé C, Vergote IB, Kristensen GB
Ten-year results of a randomised trial comparing cisplantin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer
Eur J Cancer 34 (1998) 1175-1180
131. Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Müller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C
Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer
J Clin Oncol 16 (1998) 1861-1868
130. Zeimet AG, Offner FA, Marth C, Heim K, Feichtinger H, Daxenbichler G, Dapunt O
Modulation of CA-125 release by inflammatory cytokines in human peritoneal

- mesothelial and ovarian cancer cells**
Anticancer Res 17 (1997) 3129-3132
129. Zeimet AG, Widschwendter M, Uhl-Steidl, Müller-Holzner E, Daxenbichler G, Marth C, Dapunt O
High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer
Br J Cancer 76 (1997) 1646-1651
128. Marth C
Prämenstruelles Syndrom
Pharmainformation 12 (1997) 2-4
127. Widschwendter M, Berger J, Daxenbichler G, Müller-Holzner E, Widschwendter A, Mayr A, Marth C, Zeimet AG
Loss of retinoic acid receptor- β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer
Cancer Res 57 (1997) 4158-4161
126. Marth C, Sørheim N, Kærn J, Tropé C
Tamoxifen in the treatment of recurrent ovarian carcinoma
Int J Gynecol Oncol 7 (1997) 256-261
125. Marth C, Widschwendter M, Kærn J, Jørgensen NP, Windbichler G, Zeimet AG, Tropé C, Daxenbichler G
Cisplatin resistance is associated with reduced interferon- γ -sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells
Br J Cancer 76 (1997) 1328-1332
124. Marth C, Zeimet AG, Widschwendter M, Ludescher C, Kærn J, Tropé C, Gastl G, Daxenbichler G, Dapunt O
Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells

- Cancer Res 57 (1997) 3818-3822
123. Widschwendter M, Daxenbichler G, Culig Z, Michel S, Zeimet AG, Mörtl M, Widschwendter A, Marth C
Activity of retinoic acid receptor- γ selectively binding retinoids alone and in combination with interferon- γ in breast cancer cells
Int J Cancer 71 (1997) 497-504
122. Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, Sevelda P
Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study
Gynecol Oncol 65 (1997) 461-466
121. Volgger B, Marth C, Zeimet AG, Müller-Holzner E, Ruth N, Dapunt O
Fulminant course of a microinvasive vulvar carcinoma in an immunosuppressed woman
Gynecol Oncol 65 (1997) 177-179
120. Marth C, Windbichler G, Petru E, Dirschlmaier W, Obermair A., Czerwenka K., Müller-Holzner E., Dapunt O
Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium
Gynecol Oncol 64 (1997) 121-125
119. Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, Iacobelli S, Dapunt O, Marth C
Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer
Int J Cancer 68 (1996) 34-38
118. Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, Stadlmann S, Daxenbichler G, Dapunt O

- Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125**
Gynecol Oncol 62 (1996) 384-389
117. Marth C
Tamoxifen und Endometriumkarzinom
Pharmainformation 11, 2 (1996) 1
116. Altindag ZZ, Marth C, Werner-Felmayer G, Natoli C, Zeimet AG, Wachter H, Iacobelli S, Fuchs D
Tumor associated antigen 90K activates myelomonocytic cell line THP-1
Cancer Letters 107 (1996) 143-148
115. Marth C, Daxenbichler G
Effects of taxol in choriocarcinoma cells (Reply)
Am J Obstet Gynecol 175 (1996) 1076-1077
114. Deusch E, Reider N, Marth C
Anaphylactic reaction to Latex during cesarean delivery (Case report)
Obstet Gynecol 88 (1996) 727
113. Eibl B, Schweighofer H, Nachbaur D, Marth C, Gächter A, Knapp R, Böck G, Gassner C, Schiller L, Petersen F, Niederwieser D
Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
Blood 88 (1996) 1501-1508
112. Daxenbichler G, Widschwendter M, Marth C
Sensitivity of breast and ovarian cancer cells for interferons and retinoids
Annals NY Acad Sci 784 (1996) 294-303
111. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Müller-Holzner E, Offner F, Feichtinger H, Zwierzina H, Daxenbichler G

- Different effects of interferons, interleukin-1 α , and tumor necrosis factor- α in normal (OSE) and malignant human ovarian epithelial cells**
Int J Cancer 67 (1996) 826-830
110. Marth C
Medikamentöse Behandlung der Dysmenorrhö
Pharmainformation (1996)
109. Windbichler G, Hensler E, Widschwendter M, Posch A, Daxenbichler G, Fritsch E, Marth C
Increased radiosensitivity by a combination of 9-cis-retinoic acid and interferon- γ in breast cancer cells
Gynecol Oncol 61 (1996) 387-394
108. Volgger B, Alge A, Windbichler G, Zeimet AG, Müller-Holzner E, Marth C
Sonomorphologische Beurteilung des postmenopausalen Endometriums: eine prospektive Studie
Gyn Geb Rundschau 36 (1996) 21-28
107. Offner F, Feichtinger H, Stadlmann S, Obrist P, Marth C, Klingler P, Grage B, Schmahl M, Knabbe C
Transforming growth factor- β synthesis by human peritoneal mesothelial cells: Induction by interleukin-1
Am J Pathol 148 (1996) 1679-1688
106. Widschwendter M, Daxenbichler G, Bachmair F, Müller E, Zeimet AG, Windbichler G, Uhl-Steidl M, Lang T, Marth C
Interaction of retinoic acid and interferon- α in breast cancer cell lines
Anticancer Res 16 (1996) 369-374
105. Müller-Holzner E, Marth C, Zeimet AG, Hofstädter F, Daxenbichler G
Effects of sex- and glucocorticoid steroids on breast cancer cells grown either as multicellular tumor spheroides or monolayers

- J Steroid Biochem Mol Biol 58 (1996) 13-19
104. Zeimet AG, Guadagni F, Marth C, Müller-Holzner E, Huter O, Daxenbichler G, Dapunt O
Stellenwert des Tumormarkers TAG-72 (CA 72-4) bei der Primärdiagnostik des Ovariakarzinoms
Geburtsh Frauenheilkde 55 (1995) 195-199
103. Marth C, Lang T, Widschwendter M, Müller-Holzner E, Daxenbichler G
Effects of taxol in choriocarcinoma cells
Am J Obstet Gynecol 173 (1995) 1835-1842
102. Uhl-Steidl M, Müller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, Dapunt O
Prognostic value of CD44 splice variant expression in ovarian cancer
Oncology 52 (1995) 400-406
101. Offner FA, Obrist P, Stadlmann S, Feichtinger H, Klingler P, Herold M, Zwierzina H, Hittmair A, Mikuz G, Abendstein B, Zeimet A, Marth C
IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells
Cytokine 7 (1995) 542-547
100. Widschwendter M, Daxenbichler G, Dapunt O, Marth C
Effects of retinoic acid and interferon- γ on expression of retinoic acid receptor and cellular retinoic acid binding protein in breast cancer cells
Cancer Res 55 (1995) 2135-2139
99. Marth C, Dreps A, Natoli C, Zeimet AG, Lang T, Widschwendter M, Daxenbichler G, Ullrich A, Iacobelli S
Effects of type I and II interferons on 90K antigen expression in ovarian carcinoma cells
Int J Cancer 59 (1994) 808-813
98. Lang T, Daxenbichler G, Marth C

- Effects of cytostatic agents on the expression of epidermal growth factor receptor in ovarian cancer cells**
Anticancer Res 14 (1994) 1871-1874
97. Marth C, Windbichler G, Reibnegger G, Fuchs D, Zeimet AG, Wachter H, Dapunt O
Bedeutung des Immunparameters Neopterin bei der Adnexitis
Zentralbl Gynäkol 118 (1996) 164-168
96. Marth C, Fuchs D
Activated cellular immunity in ovarian carcinoma patients
Am J Obstet Gynecol 171 (1994) 1159-1160
95. Zeimet AG, Müller-Holzner E, Marth C, Daxenbichler G
Immuncytochemical versus biochemical receptor determination in normal and tumorous tissues of the femal reproductive tract and the breast
J Ster Biochem Mol Biol 49 (1994) 365-372
94. Fuith LC, Marth C, Daxenbichler G
Serum levels of tumor marker CA 125 in viable and non-viable early pregnancy
J Tumor Marker Oncol 3 (1994) 31-33
93. Marth C
Die Behandlung der vulvovaginalen Pilzinfektion
Pharmainformation, 9 Nr. 3 (1994) 1-2
92. Marth C, Weiss G, Koza A, Reibnegger G, Daxenbichler G, Zeimet AG, Fuchs D, Wachter H, Dapunt O
Increased production of immune activation marker neopterin by colony stimulating factors in gynecological cancer patients
Int J Cancer 58(1994) 20-23
91. Alge A, Martin J, Müller-Holzner E, Marth C

- Uncommon location of persistent ectopic pregnancy following laparoscopic surgery**
Obstet Gynecol 84 (1994) 697-8
90. Marth C, Widschwendter M, Daxenbichler G
Mechanism of synergistic action of all-trans- or 9-cis-retinoic acid and interferons in breast cancer cells
J Steroid Biochem Mol Biol 47 (1993) 123-126
89. Zeimet AG, Marth C, Müller-Holzner E, Daxenbichler G, Dapunt O
Significance of thrombocytosis in patients with epithelial ovarian cancer
Am J Obstet Gynecol 170 (1994) 549-554
88. Guadagni F, Marth C, Zeimet AG, Ferroni P, Spila A, Abbolito R, Roselli M, Greiner JW, Schlom J
Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecological diseases
Am J Obstet Gynecol 171 (1994) 1183-91
87. Marth C, Weger A, Müller-Holzner E, Zeimet AG, Moncayo-Naveda H, Daxenbichler G, Reibnegger G, Fuchs D, Wachter H, Dapunt O
The prognostic value of nuclear roundness and neopterin in ovarian cancer
Eur J Cancer 29A (1993) 1863-1868
86. Melichar B, Zeimet A, Artner-Dworzak E, Schröcksnadel H, Marth C, Wachter H, Fuchs D
Association between increased urinary zinc and neopterin concentrations in women with gynaecological cancer
Tumor Diagnostik Therapie 14 (1993) 110-112
85. Öfner D, Hitmair A, Marth C, Tötsch M, Daxenbichler G, Margreiter R, Böcker W, Schmid KW
Relationship between quantity of silver stained nucleolar organizer region associated proteins (Ag- NORs) and growth rate suppression of breast cancer cell lines after interferon-gamma and 4-hydroxy-tamoxifen treatment

- Virchows Archiv B Cell Pathol 63 (1993) 359-363
84. Zeimet AG, Müller-Holzner E, Marth C, Daxenbichler G, Dapunt O
Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle
Fertil Steril 59 (1993) 1028-35
83. Dittrich C, Sevela P, Baur M, Marth C, Hudec M, Vavra N, Grunt T, Fazny B, Salzer H
In vitro and in vivo evaluation of the combination of cisplatin (CDDP) and its analogue carboplatin (CBDCA) for platinum dose intensification in ovarian carcinoma
Cancer 71 (1993) 3082-3090
82. Hetzel H, Müller-Holzner E, Marth C, Kostron H
Photodynamische Therapie bei Patientinnen mit Rezidiven gynäkologischer Malignome
Geburtsh Frauenheilkde, 53 (1993) 333-336
81. Müller-Holzner E, Zeimet AG, Daxenbichler G, Marth C, Müller L, Dapunt O
Progesterone receptors in routinely paraffin-embedded breast carcinomas and lymph node metastases
Breast Cancer Res Treat 25 (1993) 47-55
80. Marth C, Pointner E, Zeimet AG, Abfalter E, Koza A, Windbichler G, Hetzel H, Dapunt O
Die Wertigkeit von Etoposid (VP-16) in der Therapie des refraktären Ovarialkarzinoms
Geburtsh Frauenheilkde 53 (1993) 303-307
79. Marth C, Tabarelli M, Dapunt O
Hormonsubstitution im Klimakterium: Nutzen und Risiko
Pharmainformation 7 (1992) 1-3
78. Öfner D, Hittmair A, Marth C, Öfner C, Tötsch M, Daxenbichler G, Mikuz G, Margreiter

- R, Schmid KW
Relationship between quantity of silver stained nucleolar organizer regions associated proteins (Ag-NORs) and population doubling time in ten breast cancer cell lines
Path Res Pract 188 (1992) 742-746
77. Zeimet AG, Thaler J, Abfalter E, Marth C, Dapunt O
Secondary leukaemias after etoposide
Lancet 340 (1992) 379-3801
76. Marth C, Judmaier W, Helweg G, Schwegel P, Wicke K, Zeimet AG, Daxenbichler G, Hetzel H
Kernspintomographie zur Verlaufskontrolle der Blasenmole
Geburtsh Frauenheilkde 52 (1992) 449-508
75. Marth C, Lang T, Cronauer MV, Doppler W, Zeimet AG, Ullrich A, Daxenbichler G
Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells
Int J Cancer 52 (1992) 311-316
74. Marth C, Zeimet AG, Böck G, Daxenbichler G
Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells
Eur J Cancer 28A, 12 (1992) 2002-2006
73. Marth C, Müller-Holzner E, Zeimet AG, Greiter E, Cronauer MV, Doppler W, Eibl B, Hynes NE, Daxenbichler G
Interferon- γ supprimiert die Expression des Onkogens HER-2 in Ovarialkarzinomzellen
Gynäkol Geburtsh Rundsch 32 (1992) 31-34
72. Madersbacher S, Klieber R, Mann K, Marth C, Tabarelli M, Wick G, Berger P
Free α -subunit, free β -subunit of human chorionic gonadotropin (hCG), and intact hCG in sera of healthy individuals and testicular cancer patients
Clin Chem 38/3 (1992) 370-376

71. Helweg G, Pessar M, Wicke K, Marth C, Sief R, zur Nedden D, Furtschegger A
Der Stellenwert der Kernspintomographie in der Diagnostik invasiver Trophoblasterkrankungen
Geburtsh Frauenheilkde 52(1992) 200-205
70. Fuith LC, Marth C, Müller-Holzner E, Zechmann W, Daxenbichler G
Enhancement of CA-125 expression by interferon- γ in ovarian carcinoma xenografts
J Tumor Marker Oncol 6 (1991) 85-89
69. Marth C, Cronauer MV, Doppler W, Öfner D, Ullrich A, Daxenbichler G
Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells
Int J Cancer 50 (1992) 64-68
68. Kirchebner P, Marth C, Mayer I, Daxenbichler G
Metabolism of E1 and E2 in Ishikawa endometrium carcinoma cells: influence of TNF- α
J Steroid Biochem Mol Biol 39 (1991) 221-222
67. Heim K, Alge A, Marth C
Anaphylactic reaction to ampicillin and severe complication in the fetus
Lancet 337 (1991) 859-861
66. Fuith LC, Müller-Holzner E, Marth C, Perkmann E, Zeimet A, Daxenbichler G
Distribution of CA 125 in placental tissues
Int J Biolog Markers 4 (1989) 78-80
65. Lechner W, Artner-Dworzak E, Heim K, Marth C, Puschendorf B
Cardiac L-myosin in the newborn child following tocolytic treatment of the mother
Int J Feto-Maternal Med 3 (1990) 242-244
64. Marth C, Müller-Holzner E, Gaugg I, Daxenbichler G, Dapunt O
Modulation of ovarian carcinoma OV632 antigen by interferons

- Oncology 49 (1992) 53-57
63. Marth C, Lang T, Koza A, Sachsenmaier M, Hetzel H
Vergleich der konventionellen Radium- mit einer High-Dose-Rate Afterloading Brachytherapie beim Zervixkarzinom
Geburtsh Frauenheilkde 51 (1991) 100-105
62. Marth C, Müller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W, Eibl B, Hynes NE, Daxenbichler G
Interferon- γ reduces expression of the protooncogene *cerbB-2* in human ovarian carcinoma cells
Cancer Res 50 (1990) 7037-7041
61. Lechner W, Keen F, Daxenbichler G, Marth C, Forstner H
Uterine relaxation by the α_1 -blocking agent doxazosin
Int J Fetomaternal Med 3 (1990) 6-8.
60. Marth C, Koza A, Müller-Holzner E, Hetzel H, Fuith LC, Dapunt O
Prognostisch relevante Faktoren beim malignen Müllerschen Misch tumor.
Geburtsh Frauenheilkde 50 (1990) 605-609
59. Marth C, Fuith LC, Müller-Holzner E, Daxenbichler G
Rapid development of resistance to tumor necrosis factor α on Ishikawa human endometrial carcinoma cells.
J Biol Regulators and Homeostatic Agents 4 (1990) 1-6
58. Lechner W, Mayr P, Marth C
Hemmung spontaner uteriner Kontraktionen durch Magnesium.
Gynäkol Rundsch. 30 (1990) 69-73
57. Marth C, Lang T, Koza A, Mayer I, Daxenbichler G
Transforming growth factor- β (TGF- β) and ovarian carcinoma cells: Regulation of proliferation and surface antigen expression

- Cancer Letters 51 (1990) 221-225
56. Daxenbichler G, Kirchebner P, Marth C, Dapunt O
Progesterone metabolism and intracellular steroid concentration in placenta, fetal membranes and myometrium before and after labour
Ann N.Y. Acad Sci 595 (1990) 440-446
55. Marth C, Madersbacher S, Herold M, Berger P, Hetzel H, Fuith LC, Daxenbichler G
Die Modulation der hCG-Synthese durch Tumornekrosefaktor- α bei JAR Chorionkarzinomzellen
Geburtsh Frauenheilkde 50 (1990) 122-123
54. Lechner W, Artner-Dworzak E, Heim K, Marth C, Puschendorf B
Herzspezifisches L-Myosin bei Schwangerschaft und Tokolysetherapie
Z Geburtsh Perinat 193 (1989) 208-210
53. Lechner W, Reider W, Rogan AM, Marth C
Myoglobin - A new approach to cardiotoxicity of cancerostatic agents
The Cancer Journal 2 (1989) 299-300
52. Schmid KW, Puelacher C, Riedler L, Stoss F, Marth C
Measuring of immunoreactivity of carcinoembryonic antigen (CEA) in colorectal cancer by microdensitometry
Pathol Res Pract 184 (1989) 382-389
51. Marth C, Mull R, Gastl G, Herold M, Steiner E, Daxenbichler G, Hetzel H, Flener R, Huber C
Die intraperitoneale Instillation von Interferon- γ zur Behandlung des refraktären Ovarialkarzinoms
Geburtsh Frauenheilkde 49 (1989) 987-991
50. Marth C, Fuith LC, Böck G, Daxenbichler G, Dapunt O
Modulation of ovarian carcinoma tumor marker CA-125 by interferon- γ

- Cancer Res 49 (1989) 6538-6542
49. Lechner W, Keen F, Marth C, Zech J
Calcium and calmodulin antagonism for inhibition of uterine contractions
Arch Gynecol Obstet 244 (1989) 137-139
48. Marth C, Koza A, Müller-Holzner E, Fuith LC, Hetzel H, Dapunt O
Parity as prognostic factor for malignant mixed Müllerian tumours
Lancet 29. April 1989, 957
47. Lechner W, Kirchebner P, Daxenbichler G, Marth C
Hemmung spontaner uteriner Kontraktionen durch Gestoden
Geburtsh Frauenheilkde 49 (1989) 259-261
46. Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler G, Dapunt O
Effects of biological response modifiers on ovarian carcinoma cell lines
Anticancer Res 9 (1989) 461-468
45. Fuith LC, Daxenbichler G, Marth C
CA 125 in human milk and serum
Gynecol Obstet Invest 28 (1989) 11-13
44. Vogetseder W, Feichtinger H, Schulz TF, Schwaeble W, Tabczewski P, Mitterer M, Böck G, Marth C, Dapunt O, Mikuz G, Dierich M
Expression of 7F7-antigen, a human adhesion molecule identical with intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblasts
Int J Cancer 43 (1989) 768-773
43. Marth C, Kirchebner P, Daxenbichler G
The role of polyamines in interferon and retinoic acid mediated synergistic antiproliferative action.
Cancer Letters 44 (1989) 55-59

42. Marth C, Helmberg M, Müller-Holzner E, Mayer I, Zech J, Tabarelli M, Daxenbichler G
Modulation of secretion of human chorionic gonadotropin by biological response modifiers on term placenta and choriocarcinoma cells.
Mol Biotherapy 1 (1989) 140-144
41. Daxenbichler G, Forsthuber EP, Marth C, Kemmler G, Wiegele J, Margreiter R, Müller L, Hausmaninger H, Manfreda D, Dapunt O
Steroid hormone receptors and prognosis in breast cancer.
Breast Cancer Res Treat 12 (1989) 267-273
40. Jakse G, Marth C, Zech J, Daxenbichler G
Antiproliferative effect of hu-interferon- γ in 674V and J82 bladder carcinoma cell lines
Urol Res 16 (1988) 403-405
39. Anderl P, Fuith LC, Daxenbichler G, Marth C, Dapunt O
Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma
Gyn Obstet Invest 25 (1988) 135-140
38. Lechner W, Artner-Dworzak E, Jarosch E, Mayr P, Pastner E, Streit B, Marth C
Untersuchungen zum Magnesiumgehalt von Myometrium, Plazenta, Nabelschnur, Blut, Fruchtwasser und Muttermilch.
Mag.-Bull. 10 (1988) 69-71
37. Daxecker F, Marth C, Daxenbichler G
Retinoic binding in melanomas of the eye and in normal chorioid
Cancer Letters 41 (1988) 119-122
36. Lechner W, Zechmann W, Mayr P, Reider W, Marth C
Zur Frage der Kardiotoxizität von Epirubicin-Cisplatin
Zent.bl. Gynäkol. 110 (1988) 429-432

35. Marth C, Daxenbichler G
Peanut agglutinin inhibits proliferation of cultured breast cancer cells.
Oncology 45 (1988) 47-50
34. Lechner W, Schinner F, Pernfuß B, Huter O, Daxenbichler G, Marth C, Pastner E
Untersuchungen zum Bleigehalt in der Muttermilch in verkehrsreichen und verkehrsarmen Gegenden Tirols.
Wiener Klin Wochenschrift 100 (1988) 519-522
33. Daxecker F, Daxenbichler G, Marth C
Cellular retinoic acid binding protein (CRABP) in retinoblastoma
Ophthalmic Paediatrics and Genetics 8 (1987) 47-48
32. Lechner W, Heim K, Zech J, Daxenbichler G, Marth C
The relation between saliva estriol levels in pregnancy and infant birth weight
Arch. Gynecol. Obstet. 241 (1987) 9-12
31. Lechner W, Daxenbichler G, Marth C
Wehenhemmung mit α -Adrenorezeptorenblockern
Z. Geburtsh. u. Perinat. 191 (1987) 102-104
30. Bartsch G, Keen F, Daxenbichler G, Marth C, Margreiter R, Brünger A, Sutter T, Rohr HP
Correlation of biochemical (receptors, endogenous tissue hormones) and quantitative morphologic (stereologic) findings in normal and hyperplastic human prostates.
Journal of Urology 137 (1987) 559-564
29. Daxecker F, Daxenbichler G, Marth C
Retinoic acid- and retinol binding proteins in melanomas and retinoblastomas
Ophthalmologica, 194 (1987) 126-127
28. Marth C, Zech J, Böck G, Mayer I, Daxenbichler G
Effects of retinoids and interferon- γ on cultured breast cancer cells in comparison

- with tumor necrosis factor- α .**
Int J Cancer 40 (1987) 840-845
27. Tilg H, Scriba M, Margreiter R, Marth C, Niederwieser D, Aulitzky W, Spielberger M, Wachter H, Huber C
Clinical presentation of CMV infection in solid organ transplant recipients and its impact on graft rejection and neopterin excretion
Clinical Transplant 1 (1987) 37-43
26. Niederwieser D, Gastl G, Rumpold H, Marth C, Kraft D, Huber C
Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT).
Br J Haematol 65 (1987) 301-305
25. Abendstein B, Marth C, Daxenbichler G
Evaluation of RU-27987 as a ligand to determine the progesterone receptor.
Clinica Chimica Acta 168 (1987) 47-54
24. Marth C, Gastl G, Zech J, Zilla P, Mayer I, Fasol R, Huber C, Daxenbichler G
Characterization of an interferon resistant mutant of the human breast cancer cell line BT-20.
J Interferon Research 7 (1987) 195 - 202
23. Marth C, Daxenbichler G, Mayer I, Gastl G, Huber C, Dapunt O
Human Interferon- γ increases adhesion of cultured carcinoma cells to to the substratum.
Cancer Letters 37 (1987) 59-69
22. Lechner W, Reider W, Hetzel H, Daxenbichler G, Marth C
Estimation of cardiotoxicity of epirubicin-cisplatin by determination of myoglobin.
Gyn Obstet Invest 22 (1986) 42-46

21. Lechner W, Huter O, Daxenbichler G, Marth C
Radioactivity in breast milk after Chernobyl.
Lancet, June 7, 1986
20. Hetzenauer A, Manzl J, Reider W, Marth C
Urodynamische Parameter vor und nach vaginaler Inkontinenzoperation.
Geburtsh Frauenheilkde 46 (1986) 27 – 29
19. Marth C, Daxenbichler G, Dapunt O
Synergistic antiproliferative effects of human recombinant interferons in combination with retinoic acid in cultured breast cancer cells.
J Natl Cancer Inst 77 (1986) 1197-1202
18. Daxenbichler G, Dürken M, Marth C, Böck G, Schauenstein K, Dapunt O
Influence of steroids and retinoic acid on peanut-lectin binding of human breast cancer cells.
Journal Ster Biochem 24 (1986) 119 – 124
17. Marth C, Buehring GC, Mayer I, Daxenbichler G
The biologically active concentrations of anti-estrogens are disproportionately elevated relative to the binding affinity for the estrogen receptor.
Annals NY Acad Sci 464 (1986) 509-510
16. Gastl G, Marth C, Leiter E, Gatttringer C, Mayer I, Daxenbichler G, Flener R, Huber C
Effects of human recombinant interferon- α -2-arg and - γ on human breast cancer lines: Dissociation of antiproliferative activity and induction of HLA-DR antigen expression.
Cancer Res 45 (1985) 2957 – 2961
15. Marth C, Böck G, Daxenbichler G
Effect of retinoic acid and 4-hydroxyphenylretinamide on proliferation and cell cycle of cultured human breast cancer cells.
J Natl Cancer Inst 75 (1985) 871 – 875

14. Marth C, Daxenbichler G
Pulsatile versus continuous estradiol exposure of cultured ZR-75-1 human breast cancer cells.
J Steroid Biochem 23 (1985) 567 – 572
13. Daxecker F, Marth C
Korrelationsanalyse emmetroper und ametroper Augen
Fortschritte der Ophthalmologie 82 (1985) 94 – 97
12. Lechner W, Marth C, Daxenbichler G
Correlation of estriol levels in saliva, plasma, and urine of pregnant women.
Acta Endocrinol 109 (1985) 266 - 268
11. Daxenbichler G, Daxecker F, Marth C
High concentration of retinoic acid binding protein in a retinoblastoma.
Experimental Eye Research 40 (1985) 495 – 496
10. Denz H, Lechleitner M, Marth C, Daxenbichler G, Gastl G, Braunsteiner H
Effect of human recombinant α -2 and γ -interferon on the growth of human cell lines from solid tumors and hematologic malignancies in vitro.
J Interferon Research 5 (1985) 147 - 157
9. Müller-Holzner E, Marth C, Kofler E, Daxenbichler G, Hofstädter F
Lectin binding sites in cultured human breast cancer cells.
Breast Cancer Treat Res 5 (1985) 277 – 283
8. Marth C, Mayer I, Daxenbichler G
Effect of retinoic acid and 4-hydroxy-tamoxifen on human breast cancer cells.
Biochem Pharmacol 33 (1984) 2217 – 2221
7. Gastl G, Niederwieser D, Marth C, Huber H, Egg D, Schuler G, Margreiter R, Braunsteiner H, Huber C
Human large granular lymphocytes (LGL) and their relationship to natural killer cell

- activity in various disease states.**
Blood 64 (1984) 288 – 295
6. Daxecker F, Daxenbichler G, Marth C
Vitamin-A-Säure bindendes Protein in intraokularen Tumoren.
Klinische Monatsblätter der Augenheilkunde, 185 (1984) 335 – 337
 5. Marth C, Daxenbichler G, Buehring GC, Hofstädter F, Dapunt O
Inhibition of the estradiol induced growth of cultured human breast cancer cells by the anti-estrogens tamoxifen, desmethyltamoxifen, 4-hydroxy-tamoxifen and enclomiphene.
Biochem Pharmacol 33 (1984) 3951 – 3956
 4. Bartsch G, Brügger A, Schweikert U, Hintner H, Stanzl U, Marth C, Daxenbichler G, Rohr HP
The importance of stromal tissue in benign prostatic hyperplasia: morphological, immunofluorescence and endocrinological investigations in new approaches to the study of benign prostatic hyperplasia.
Prog Clin Biol Res 145 (1984) 159 – 179
 3. Daxecker F, Janka C, Marth C
Messung axialer Abschnitte bei emmetropen und hyperopen Augen mit aequatorialen Degenerationen.
Klin Monatsbl Augenh 183 (1983) 400- 401
 2. Bichler E, Daxenbichler G, Marth C
Vitamin A status and retinoid-binding proteins in carcinomas of the head and neck region.
Oncology 40 (1983) 336 – 339
 1. Jerabek R, Daxenbichler G, Marth C, Dapunt O
Steroidhormonrezeptoren und Therapie beim fortgeschrittenen Mammacarcinom.
Tumordiagnostik & Therapie 4 (1983) 7-14

